Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue (PGSRT): a Randomized Clinical Trial
This study will fill a scientific gap in the current knowledge providing data for evaluation of the palatal augmentation prosthesis as a therapeutic modality in a robust scientific randomized prospective clinical trial. Positive outcomes from this study have the potential to dramatically alter the most common morbidity of oral cancer therapy, namely speech and swallowing function in a population of patients with T1/T2 tumors of the tongue who are not currently routinely recommended for a palatal augmentation prosthesis.
Palatal Augmentation Prosthesis (PAP)
Study Arms / Comparison Groups
Prosthesis + Articulation Therapy
Description: This arm will receive a palatal augmentation prosthesis with standard articulation therapy, and is the study arm.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
January 2, 2018
Primary Completion Date
Inclusion Criteria: - Patients with a new diagnosis of a T1/T2 tongue cancer Exclusion Criteria: - Patients with recurrent disease - Patients with a history of prior head and neck radiation therapy - Patients who lack adequate maxillary dentition to support a palatal augmentation prosthesis
18 Years - N/A
Accepts Healthy Volunteers
Stephanie M Munz, DDS, 734 936-8289, [email protected]
University of Michigan
Stephanie M Munz, DDS, Principal Investigator, University of Michigan